| Revision as of 07:47, 12 March 2003 editSusan Mason (talk | contribs)1,955 editsNo edit summary← Previous edit | Revision as of 07:47, 12 March 2003 edit undoSusan Mason (talk | contribs)1,955 editsmNo edit summaryNext edit → | ||
| Line 1: | Line 1: | ||
| '''Zidovudine''' ('''AZT''') was the first ] ] to be approved for treating ]. It was originally developed to treat ], but was also found to block the action of the "]" ] that HIV uses to replicate its ] for splicing into the ] of a target ]. Side-effects include ]. ] first synthesized the drug in ], under a ] ] ]. The formula was later bought by ]. The drug typically sells for ~]8 per |
'''Zidovudine''' ('''AZT''') was the first ] ] to be approved for treating ]. It was originally developed to treat ], but was also found to block the action of the "]" ] that HIV uses to replicate its ] for splicing into the ] of a target ]. Side-effects include ]. ] first synthesized the drug in ], under a ] ] ]. The formula was later bought by ]. The drug typically sells for ~]8 per dose and is manufactured at ~$0.63 per dose | ||
Revision as of 07:47, 12 March 2003
Zidovudine (AZT) was the first antiviral drug to be approved for treating HIV. It was originally developed to treat cancer, but was also found to block the action of the "reverse transcriptase" enzyme that HIV uses to replicate its RNA for splicing into the DNA of a target cell. Side-effects include anemia. Jerome Horowitz first synthesized the drug in 1964, under a US National Institutes of Health grant. The formula was later bought by Glaxo-Wellcome. The drug typically sells for ~$8 per dose and is manufactured at ~$0.63 per dose